Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ. 2015;350:g7773.
Article PubMed PubMed Central Google Scholar
Keeney E, Thom H, Turner E, Martin RM, Morley J, Sanghera S. Systematic review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis. Value Health. 2022;25(1):133–46.
Hiligsmann M, Wyers CE, Mayer S, Evers SM, Ruwaard D. A systematic review of economic evaluations of screening programmes for cardiometabolic diseases. Eur J Public Health. 2017;27(4):621–31.
Mandrik O, Hahn AI, Catto JWF, Zauber AG, Cumberbatch M, Chilcott J. Critical appraisal of decision models used for the economic evaluation of bladder cancer screening and diagnosis: a systematic review. Pharmacoeconomics. 2023;41(6):633–50.
Article PubMed PubMed Central Google Scholar
Mandrik OL, Severens JLH, Bardach A, Ghabri S, Hamel C, Mathes T, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report. Value Health. 2021;24(4):463–72.
Pineda-Antunez C, Seguin C, van Duuren LA, Knudsen AB, Davidi B, Nascimento de Lima P, et al. Emulator-based Bayesian calibration of the CISNET colorectal cancer models. Med Decis Making. 2024;44(5):543–53.
Article PubMed PubMed Central Google Scholar
Trentham-Dietz A, Alagoz O, Chapman C, Huang X, Jayasekera J, van Ravesteyn NT, et al. Reflecting on 20 years of breast cancer modeling in CISNET: recommendations for future cancer systems modeling efforts. PLoS Comput Biol. 2021;17(6):e1009020.
Article CAS PubMed PubMed Central Google Scholar
Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol. 2007;25(2):203–8.
Keeney E, Thom H, Turner E, Martin RM, Sanghera S. Using a modified Delphi approach to gain consensus on relevant comparators in a cost-effectiveness model: application to prostate cancer screening. Pharmacoeconomics. 2021;39(5):589–600.
Article PubMed PubMed Central Google Scholar
NHS England. UK National Screening Committee: screening in healthcare. 10 May 2024. Available from: https://www.gov.uk/guidance/principles-of-population-screening/principles-of-screening#:~:text=The%20UK%20NSC%20does%20not,no%20symptoms%20or%20particular%20risk. Accessed 7 Jul 2025.
NHS England. Bowel cancer screening programme standards: valid for data collected from 1 April 2018. 4 June 2025. Available from: https://www.gov.uk/government/publications/bowel-cancer-screening-programme-standards/bowel-cancer-screening-programme-standards-valid-for-data-collected-from-1-april-2018?utm_source=chatgpt.com. Accessed 12 Feb 2026.
Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 2007;96(3):338–41.
Last JM, International Epidemiological A. A dictionary of epidemiology. 4th ed. Oxford: Oxford University Press; 2001.
Squires H, Chilcott J, Akehurst R, Burr J, Kelly MP. A framework for developing the structure of public health economic models. Value Health. 2016;19(5):588–601.
Luijendijk HJ. How to create PICO questions about diagnostic tests. BMJ Evid Based Med. 2021;26(4):155–7.
Article PubMed PubMed Central Google Scholar
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310.
Fasseeh A MA, Nagy B., Nemeth B, Szilberhorn L. The role of modelling in economic evaluations in health care: Eötvös University Press; 2019. p. 72.
Thomas C, Mandrik O, Whyte S. Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England. Prev Med. 2022;162:107131.
Mandrik O, Thomas C, Akpan E, Catto JWF, Chilcott J. Home urine dipstick screening for bladder and kidney cancer in high-risk populations in England: a microsimulation study of long-term impact and cost-effectiveness. Pharmacoeconomics. 2025;43(4):441–52.
Dennison RA, Usher-Smith JA, John SD. The ethics of risk-stratified cancer screening. Eur J Cancer. 2023;187:1–6.
Dunlop K, Rankin NM, Smit AK, Salgado Z, Newson AJ, Keogh L, et al. Acceptability of risk-stratified population screening across cancer types: qualitative interviews with the Australian public. Health Expect. 2021;24(4):1326–36.
Article PubMed PubMed Central Google Scholar
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, Incorporated; 1996.
Karlsson A, Jauhiainen A, Gulati R, Eklund M, Grönberg H, Etzioni R, et al. A natural history model for planning prostate cancer testing: calibration and validation using Swedish registry data. PLoS ONE. 2019;14(2):e0211918.
Article CAS PubMed PubMed Central Google Scholar
NHS England. NHS screening programmes in England: 2019 to 2020. 16 February 2023 Available from: https://www.gov.uk/government/publications/nhs-screening-programmes-annual-report/nhs-screening-programmes-in-england-2019-to-2020. Accessed 28 Nov 2025.
Keeling MJ, Ross JV. On methods for studying stochastic disease dynamics. J R Soc Interface. 2008;5(19):171–81.
Article CAS PubMed PubMed Central Google Scholar
Salisbury A, Pearce A, Howard K, Norris S. Impact of structural differences on the modeled cost-effectiveness of noninvasive prenatal testing. Med Decis Making. 2024;44(7):811–27.
Article PubMed PubMed Central Google Scholar
Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MDS, Houweling H, et al. Universal HIV screening of pregnant women in England: cost effectiveness analysis. BMJ. 1999;318(7199):1656–60.
Article CAS PubMed PubMed Central Google Scholar
Roberts MC, Dotson WD, DeVore CS, Bednar EM, Bowen DJ, Ganiats TG, et al. Delivery of cascade screening for hereditary conditions: a scoping review of the literature. Health Aff (Millwood). 2018;37(5):801–8.
Article PubMed PubMed Central Google Scholar
McKnight D, Morales A, Hatchell KE, Bristow SL, Bonkowsky JL, Perry MS, et al. Genetic testing to inform epilepsy treatment managementfFrom an international study of clinical practice. JAMA Neurol. 2022;79(12):1267–76.
Article PubMed PubMed Central Google Scholar
Botkin JR. Ethical issues in pediatric genetic testing and screening. Curr Opin Pediatr. 2016;28(6):700–4.
Article PubMed PubMed Central Google Scholar
Lund JL, Rivera MP, Su IH, Long JM, Chen X, Pak J, et al. Estimating the effects of cancer screening in clinical practice settings: the role of selective uptake and suboptimal adherence along the cancer screening continuum. Cancer Epidemiol Biomarkers Prev. 2024;33(8):984–8.
Article PubMed PubMed Central Google Scholar
Weller DP, Campbell C. Uptake in cancer screening programmes: a priority in cancer control. Br J Cancer. 2009;101 Suppl. 2(Suppl. 2):S55–9.
Article PubMed PubMed Central Google Scholar
Iragorri N, Spackman E. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis. Public Health Rev. 2018;39:17.
Article PubMed PubMed Central Google Scholar
Sekiguchi M, Igarashi A, esaki M, saito Y, Kobayashi N, Matsuda T. Cost-effectiveness analysis of fecal immunochemical test- and colonoscopy-based colorectal cancer screening across varying uptake rates. DEN Open. 2026;6(1):e70236.
Masuku SD, Mandrik O, Mdege ND, Mishra G, Muwonge R, Meyer-Rath G, et al. Breast cancer screening using clinical breast examination: a cost-effectiveness analysis for South Africa. Value Health Reg Issues. 2025;49:101127.
Article PubMed PubMed Central Google Scholar
Davenport MS. Incidental findings and low-value care. AJR Am J Roentgenol. 2023;22
Comments (0)